Physician profile
Brandy Preston
NPI 1417471103
$3,629.75
in general payments reported to CMS, 2019-2025
29 companies · $854 in 2025
The $854 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $923 · 2022: $848 · 2023: $448 · 2024: $558 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.68 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.95 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.67 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Novo Nordisk INC | $184.31 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Redhill Biopharma INC. | $170.49 | 2021-2023 | |
| Pfizer INC. | $131.23 | 2023-2025 | |
| Exact Sciences Corporation | $126.07 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $99.09 | 2023-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.45 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $74.21 | 2021-2023 | Entyvio |
| Abbott Laboratories | $70.62 | 2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $68.35 | 2025 | |
| Merck Sharp & Dohme LLC | $63.52 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Biotech, INC. | $62.35 | 2022-2023 | Stelara |
| Nestle Healthcare Nutrition INC. | $61.88 | 2021 | |
| Amgen INC. | $59.02 | 2023-2025 | Otezla, Repatha, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45.35 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Celgene Corporation | $43.36 | 2022-2023 | Zeposia |
| Evoke Pharma, INC. | $42.55 | 2021-2023 | Gimoti |
| Scpharmaceuticals INC. | $39.53 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $37.65 | 2024 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $37.34 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.38 | 2023-2024 | |
| Genzyme Corporation | $26.23 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.26 | 2025 | Rexulti |
| Astellas Pharma US INC | $19.69 | 2025 | Veozah |
| Abiomed | $17.57 | 2024 | Impella |
| Qol Medical, LLC | $17.00 | 2021 | |
| Ardelyx, INC. | $15.44 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Preston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.